依达拉奉右莰醇联合血管介入术治疗急性脑梗死的疗效及对患者血清Lp-PLA_(2)、NSE水平和血小板功能的影响

Efficacy of edaravone dexborneol combined with vascular intervention in the treatment of acute cerebral infarction and the influence on serum Lp-PLA_(2)and NSE levels and platelet function

目的观察依达拉奉右莰醇联合血管介入术治疗急性脑梗死(ACI)的疗效,并探讨其对患者血清脂蛋白相关磷脂酶A2[Lp-PLA_(2)]、神经元特异性烯醇化酶(NSE)水平和血小板功能的影响。方法选取2021年1月至2022年2月宝鸡市第三医院与宝鸡市高新医院收治的105例ACI患者作为研究对象,采用分层区组随机化方法,按各医院分层,按照1∶1比例将患者分为对照组52例和观察组53例,两组患者均行常规治疗和血管介入手术治疗,此外,对照组给予依达拉奉注射液,观察组给予依达拉奉右莰醇注射用浓溶液,两组患者均治疗14d。比较两组患者治疗后的临床疗效,以及治疗前后的血清Lp-PLA_(2)、NSE水平、血小板功能和并发症发生情况。结果观察组患者的治疗总有效率为94.34%,明显高于对照组的80.77%,差异有统计学意义(P<0.05);治疗后,观察组患者的血清Lp-PLA_(2)、NSE分别为(169.46±14.68)mg/L、(7.96±0.82)mg/L,明显低于对照组的(192.36±16.04)mg/L、(9.78±0.58)mg/L,差异均有统计学意义(P<0.05);治疗后,观察组患者的血小板黏附率、血小板聚集率、CD62p和选择素分别为(35.89±3.56)%、(29.10±3.46)%、(2.83±0.50)%、(10.88±2.17)mg/L,明显低于对照组的(39.68±3.48)%、(31.57±3.66)%、(3.17±0.49)%、(12.03±2.09)mg/L,差异均有统计学意义(P<0.05);治疗后,观察组患者的并发症总发生率为3.77%,略低于对照组的7.69%,但差异无统计学意义(P>0.05)。结论依达拉奉右莰醇联合血管介入术治疗急性脑梗死的疗效较好,其可降低患者血清Lp-PLA_(2)、NSE水平,改善血小板功能。

Objective To observe the efficacy of edaravone dexborneol combined with vascular intervention in the treatment of acute cerebral infarction(ACI),and investigate the influence on serum lipoprotein-associated phospholi-pase A2[Lp-PLA_(2)],neuron-specific enolase(NSE)levels,and platelet function.Methods A total of 105 patients with ACI admitted to Baoji Third Hospital and Baoji High-tech Hospital from January 2021 to February 2022 were se-lected as the research subjects.They were divided into the control group(52 cases)and the observation group(53 cases)by stratified blocked randomization method.All patients were given conventional treatment and vascular interventional operation.The control group was treated with edaravone injection,while the observation group was treated with edara-vone dexborneol injection.All patients were treated for 14 days.The two groups were compared in terms of clinical effi-cacy after treatment,serum Lp-PLA_(2)and NSE levels before and after treatment,platelet function,and the incidence of complications.Results The total treatment response rate in the observation group was 94.34%,significantly higher than 80.77%in the control group,with a statistically significant difference(P<0.05).After treatment,serum Lp-PLA_(2)and NSE levels,platelet adhesion rate,platelet aggregation rate,CD62p level,and selectin level in the observation group were(169.46±14.68)mg/L,(7.96±0.82)mg/L,(35.89±3.56)%,(29.10±3.46)%,(2.83±0.50)%,and(10.88±2.17)mg/L,significantly lower than(192.36±16.04)mg/L,(9.78±0.58)mg/L,(39.68±3.48)%,(31.57±3.66)%,(3.17±0.49)%,and(12.03±2.09)mg/L in the control group,with statistically significant differences(P<0.05).After treatment,the total inci-dence of complications in the observation group was 3.77%,slightly lower than 7.69%in the control group,without sta-tistically significant difference(P>0.05).Conclusion Edaravone dexborneol combined with vascular intervention is ef-fective in the treatment of ACI,which can lower serum Lp-PLA_(2)and NSE levels,and improve platelet function.